Genoskin Raises $8.7 Million Series A to Support Drug Development with Ethical, Human-Based Models

Genoskin, bringing unparalleled expertise in skin biology and immunology to advance research and drug development efforts led by Pascal Descargues, Frederick Roques, Vicky Tourte, Nicolas Gaudenzio, Anna Falkovsky, and Lorna Santos, has secured  $8.7 million in Series A led by OCCTE (FPCI Occidev Impacts), Captech Santé, GSO Innovation, and CA Toulouse 31 Initiatives (CAT31i), the round includes $5.4 million (€5M) in equity investment and $3.3 million (€3M) in non-dilutive financing in structured bank debt, provided by Bpifrance and local banking partners: BNP Paribas, Caisse d’Epargne, and Crédit Agricole. 

Genoskin plans to double its workforce and expand globally, with new facilities in Salem, MA, and Toulouse, France. Genoskin develops ex vivo human skin models that offer more predictive insights into drug and device safety than traditional animal testing. Using ethically sourced skin that remains viable for up to seven days, its platforms provide biotech, pharma, and cosmetics companies with a sustainable, human-relevant alternative.

To meet rising global demand, Genoskin is expanding with new facilities in Salem, MA (2026) and Toulouse, France (2027). The sites will double production capacity for its human skin models and add U.S. production of fresh primary mast cells for next-day delivery. Increased automation will further scale operations while ensuring strict quality control, enabling Genoskin to deliver efficient, reliable services that help customers develop safer, more effective therapies.

Alongside its infrastructure expansion, Genoskin is advancing new biosimulation platforms and human immune models aimed at reducing reliance on animal testing. By 2027, these innovations will support immune-centric services, reinforcing its leadership in immunotoxicology and delivering critical insights into drug safety and efficacy.

Genoskin is redefining preclinical testing with scalable, ethical, human-relevant alternatives to animal models. As regulators push for more humane and effective methods, the company is well-positioned to lead in delivering safer, more predictive drug development insights worldwide.